Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan

Abstract

Objective: The novel potassium-competitive acid blocker, vonoprazan, provides rapid and effective acid suppression. The aim of this study is to evaluate the long-term outcomes of patients with symptomatic gastroesophageal reflux disease (GERD) treated with vonoprazan.

Methods: This retrospective cohort study included 55 patients with symptomatic GERD treated with vonoprazan who have been followed for more than one year. The effectiveness of vonoprazan on gastrointestinal symptoms was evaluated using the Izumo scale, a self-reported questionnaire reflecting quality of life related to various abdominal symptoms.

Results: These 55 patients with symptomatic GERD had non-erosive reflux disease (n = 30) or erosive esophagitis (n = 25). Vonoprazan (10 mg) for one month improved GERD symptoms in 89% (responders) and the improvement was maintained at one year in 82% without additional treatment. One-year maintenance therapy resulted in sustained resolution of GERD symptoms in 47%. Of the 49 responders, nine patients had relapse of GERD symptoms and dose escalation of vonoprazan improved the symptoms in six patients. Postprandial distress and the presence of erosive esophagitis before starting vonoprazan were identified as significant negative and positive predictors of sustained resolution of GERD symptoms for one year, respectively. Epigastric pain, postprandial distress, constipation and diarrhea were significantly improved at one-month and maintained at one year. After one-year of treatment, the endoscopic healing rate of erosive esophagitis was 95%.

Conclusion: One-year treatment with vonoprazan significantly improves GERD symptoms and endoscopic healing of erosive esophagitis is satisfactory. The long-term use of vonoprazan is effective and useful to control GERD.

Keywords:

• Gastroesophageal reflux disease
• dyspepsia
• potassium-competitive acid blocker
• esophagitis
• outcome measure

Disclosure statement

Author S.S. received honoraria from Takeda Pharmaceuticals. Author H.O. received honoraria from Takeda and Otsuka Pharmaceuticals. Author H.S. received a research grant from Takeda Pharmaceuticals. Author Y.M. received honoraria from Takeda and Otsuka Pharmaceuticals. Author H.Y. has received research grants and honoraria from Takeda and Otsuka Pharmaceuticals. Other authors declare no conflicts of interest regarding this study. The funding source had no role in the design, practice or analysis of this study.